Drug Chatter -- Tracking biopharma stock chatter

💊 Get Accurate, Objective, and Timely Intelligence From DrugPatentWatch

Profile for Jazz Pharmaceuticals plc (JAZZ)

« Back to company index

JAZZ Chatter Timeline

Stock Ticker for JAZZ

Most Active Tweeters for JAZZ

UserTweets
@TShortalgo 7
@Gambiste1 6
@Beeken_health 6
@Slayer10Stock 5
@thudderwicks 3

Recent Tweets for JAZZ

TShortalgo @TShortalgo
$JAZZ Trading Ideas | Awaiting Buy signal. 100% Profitability based on 9 trades. Profit factor is 100. Learn more a… https://t.co/rpbAcvvVB2
January 27th 2023, 10:01am
newsfilterio @newsfilterio
Form SC 13G/A (statement of acquisition of beneficial ownership by individuals) filed with the SEC $JAZZ https://t.co/AA2YYtoUxk
January 27th 2023, 9:01am
Slayer10Stock @Slayer10Stock
$JAZZ Put-Call ratio by Volume => 0.24 @ 2023-02-17. Learn more at https://t.co/54bj3mKa5j. #JAZZSTOCK #puts https://t.co/eEbfa0EX7h
January 27th 2023, 7:01am
TShortalgo @TShortalgo
$JAZZ Trading Ideas | Awaiting Buy signal. 90.91% Profitability based on 11 trades. Profit factor is 5.75. Learn mo… https://t.co/1jSlXSia3T
January 26th 2023, 10:01pm
TopStockAlerts1 @TopStockAlerts1
$JAZZ FDA says it will not regulate CBD and calls on Congress to act https://t.co/UcdZCdp3qH
January 26th 2023, 7:01pm
newsfilterio @newsfilterio
U.S. FDA calls for new regulatory framework for use of cannabis compound CBD $JAZZ https://t.co/oXcQvl9M2U
January 26th 2023, 6:01pm
TShortalgo @TShortalgo
$JAZZ Trading Ideas | Awaiting Buy signal. 90.91% Profitability based on 11 trades. Profit factor is 5.75. Learn mo… https://t.co/K0pCvvVhOG
January 26th 2023, 3:01pm
Slayer10Stock @Slayer10Stock
$JAZZ Put-Call ratio by Volume => 0.24 expiration 2023-02-17. #calls #puts #options ? Chart by… https://t.co/DGzTPxcv8L
January 26th 2023, 1:01pm
Slayer10Stock @Slayer10Stock
$JAZZ Put-Call ratio by Volume => 0.24 @ 2023-02-17. Learn more at https://t.co/54bj3mKa5j. #JAZZSTOCK #puts https://t.co/SL5b0h8dxC
January 26th 2023, 6:01am
SmallTimePotato @SmallTimePotato
RT @JD4for4: Niskanen Center files amicus brief in support of narcolepsy patients in $JAZZ v. $AVDL - Niskanen Center — appeal hearing path…
January 25th 2023, 10:01pm
JD4for4 @JD4for4
Niskanen Center files amicus brief in support of narcolepsy patients in $JAZZ v. $AVDL - Niskanen Center — appeal h… https://t.co/BTP21x1SQY
January 25th 2023, 10:01pm
kjerath @kjerath
RT @bobjohn83869058: $avdl up on big volume and big blocks. Appeal hearing on February 14th should rule in their favor and against $jazz.…
January 25th 2023, 8:01pm
HScottMatusow @HScottMatusow
GlycoMimetics (GLYC) is a Bigger Deal Than Most Realize https://t.co/4nN6lLHEW4 via @HScottMatusow $GLYC $JAZZ… https://t.co/Ya2Et2fmZt
January 25th 2023, 6:01pm
TShortalgo @TShortalgo
$JAZZ Trading Ideas | Awaiting Buy signal. 100% Profitability based on 6 trades. Profit factor is 100. Learn more a… https://t.co/W0dlQBljIr
January 25th 2023, 5:01pm
TShortalgo @TShortalgo
$JAZZ Trading Ideas | Awaiting Buy signal. 100% Profitability based on 6 trades. Profit factor is 100. Learn more a… https://t.co/zF8dHM2jAF
January 25th 2023, 9:01am
Gambiste1 @Gambiste1
RT @SnupSnus: @drug_smolecules Or $JAZZ/daiichi all more advanced
January 24th 2023, 11:01pm
astockwatch1 @astockwatch1
$JAZZ $ZYME Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evalua… https://t.co/GQchxoPO6a
January 24th 2023, 7:01pm
TShortalgo @TShortalgo
$JAZZ Trading Ideas | Awaiting Short signal. 100% Profitability based on 3 trades. Profit factor is 100. Learn more… https://t.co/f9jHpDjjzT
January 24th 2023, 5:01am
Slayer10Stock @Slayer10Stock
$JAZZ Put-Call ratio by Volume => 0.45 @ 2023-02-17. Learn more at https://t.co/54bj3mKa5j. #JAZZSTOCK #stockmarket https://t.co/EFUitVo8ur
January 23rd 2023, 4:01pm
SnupSnus @SnupSnus
@drug_smolecules Or $JAZZ/daiichi all more advanced
January 23rd 2023, 11:01am
TShortalgo @TShortalgo
$JAZZ Trading Ideas | Awaiting Short signal. 100% Profitability based on 3 trades. Profit factor is 100. Learn more… https://t.co/lZGovHwiIc
January 23rd 2023, 7:01am
Slayer10Stock @Slayer10Stock
$JAZZ Put-Call ratio by Volume => 0.45 @ 2023-02-17. Learn more at https://t.co/54bj3mKa5j. #JAZZSTOCK #stockmarket https://t.co/coFfm0K5rd
January 22nd 2023, 12:01am
Gambiste1 @Gambiste1
RT @Beeken_health: $JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/xVQepr65zw
January 21st 2023, 7:01pm
Beeken_health @Beeken_health
$JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/xVQepr65zw
January 21st 2023, 5:01pm
Beeken_health @Beeken_health
$JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/hJQRqX58k9
January 21st 2023, 4:01pm
Gambiste1 @Gambiste1
RT @Beeken_health: $JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/7dJtEC865w
January 21st 2023, 2:01am
Gambiste1 @Gambiste1
RT @Beeken_health: $JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/AXUTGOQxrG
January 21st 2023, 2:01am
Gambiste1 @Gambiste1
RT @Beeken_health: $JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/zvQNBmjTGI
January 21st 2023, 2:01am
Beeken_health @Beeken_health
$JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/zvQNBmjTGI
January 21st 2023, 1:01am
Beeken_health @Beeken_health
$JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/7dJtEC865w
January 21st 2023, 1:01am
Beeken_health @Beeken_health
$JAZZ - Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival https://t.co/AXUTGOQxrG
January 21st 2023, 12:01am
newsfilterio @newsfilterio
Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC $JAZZ https://t.co/3Lt7mx0t1T
January 20th 2023, 11:01pm
ChartMill @ChartMill
$JAZZ was analyzed by 24 analysts. The buy consensus is at 83%. So analysts seem to be very confident about $JAZZ.… https://t.co/cxBWmhVmUj
January 20th 2023, 5:01pm
SeekingAlpha @SeekingAlpha
$JAZZ - Jazz Pharmaceuticals (JAZZ) Presents At 41st Annual Healthcare Conference - Slideshow.… https://t.co/e0NtqSq4hB
January 20th 2023, 12:01pm
Gambiste1 @Gambiste1
RT @sunrgu: What are the chances of $JAZZ acquiring $ZYME . Institutional investors buying again but stock going nowhere.
January 20th 2023, 2:01am
sunrgu @sunrgu
What are the chances of $JAZZ acquiring $ZYME . Institutional investors buying again but stock going nowhere.
January 20th 2023, 2:01am
YaelGruenbaum @YaelGruenbaum
Go bi specifics ? https://t.co/tDaAhQSZSS and congrats to $JAZZ
January 19th 2023, 10:01pm
TeamofStockTra @TeamofStockTra
$JAZZ - Jazz Pharmaceuticals, Zymeworks Announce Positive Results From Phase 2 Trial of Esophageal Cancer Treatment
January 19th 2023, 5:01pm
MarcJacksonLA @MarcJacksonLA
$JAZZ $ZYME Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evalua… https://t.co/OUye26v6Z1
January 19th 2023, 3:01pm
AlertTrade @AlertTrade
RT @Briefingcom: $JAZZ: Jazz Pharma and Zymeworks (ZYME) announce tolerability and efficacy results, including the first overall... https:/…
January 19th 2023, 2:01pm
Briefingcom @Briefingcom
$JAZZ: Jazz Pharma and Zymeworks (ZYME) announce tolerability and efficacy results, including the first overall... https://t.co/6kApxkT1ey
January 19th 2023, 2:01pm
raygachette @raygachette
RT @BertrandBio: $Jazz Pharmaceuticals and Zymeworks $ZYME Announce 84% OS at 18 Mo from Phase 2 Trial Evaluating Zanidatamab in HER2+ Meta…
January 19th 2023, 2:01pm
OpenOutcrier @OpenOutcrier
$ZYME (+10.0% pre) Jazz Pharmaceuticals $JAZZ, Zymeworks (ZYME) Announce 84% OS at 18 Months from Phase 2 Trial Eva… https://t.co/Uv8wfA3ajl
January 19th 2023, 1:01pm
StckPro @StckPro
$JAZZ $ZYME NEW ARTICLE : Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmace… https://t.co/iSNPCFudWw
January 19th 2023, 1:01pm
Beeken_health @Beeken_health
$JAZZ $ZYME - Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals https://t.co/D7lWDQRFfv
January 19th 2023, 1:01pm
BertrandBio @BertrandBio
$Jazz Pharmaceuticals and Zymeworks $ZYME Announce 84% OS at 18 Mo from Phase 2 Trial Evaluating Zanidatamab in HER… https://t.co/PUWDmkh4KS
January 19th 2023, 1:01pm
thudderwicks @thudderwicks
$JAZZ, $ZYME ”The median duration of response was 20.4 months with a median progression-free survival (mPFS) of 12.… https://t.co/v2zmJMMALI
January 19th 2023, 12:01pm
thudderwicks @thudderwicks
$JAZZ, $ZYME “Treatment with zanidatamab resulted in a confirmed objective response rate (cORR) of 79%, a disease c… https://t.co/he4bQuZWXt
January 19th 2023, 12:01pm
thudderwicks @thudderwicks
$JAZZ, $ZYME “The preliminary results showed that, at the time of analysis, the median OS had not yet been reached… https://t.co/7HE75moQaF
January 19th 2023, 12:01pm
FlashAlert_me @FlashAlert_me
$JAZZ [15s. delayed]: Issued Press Release on January 19, 07:45:00: Jazz Pharmaceuticals and Zymeworks Announce 84%… https://t.co/7oRebSlFyz
January 19th 2023, 12:01pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2023. All rights reserved.